Reimagining Treatments for Complex Disease

NED Biosystems™ was founded to develop safe, efficacious, and comprehensive “systems” treatments for complex disease, beginning with the development of the patented NED-170 for treatment of cancer. A systems-based approach to treat disease comprehensively targets the behavior of the entire biological system instead of a single component.

NED-170 takes a systems approach that combines repurposed, oral agents well-documented in humans to affect critical cancer disease-driver processes at doses that lack customary toxicity and side effects.

50%-80% of all cancer patients have no genetically sequenced “matched” therapy options.  NED-170 is designed to initially treat these patients.

When the pandemic hit NED deployed its systems methodology to develop NED-260 to be a universal antiviral treatment for existing infectious diseases and those not yet known.

NED-260 is designed to protect multiple pathways within patients’ cells from attack by a broad range of viruses. NED-260’s treatment goal is to act early in the infection process to minimize, or eliminate, the advancement to severe disease, ideally allowing many patients to recover at home.

NED-260 and NED-170 strive to lessen the impact of two of the deadliest diseases faced by humanity today.